Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with or without Temozolomide in Low-Grade Glioma
NCT02023905Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Mar 2014
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in low-grade glioma (LGG), sponsored by University of California, San Francisco. Started Mar 2014; status: terminated.
02
Drugs
everolimus
03
Conditions
low-grade glioma (LGG)
Beyond the preview
Go deeper on NCT02023905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023905.